Pharmacogenetics of nonsteroidal anti-inflammatory drugs

• Published in: The pharmacogenomics journal Vol. 12; no. 6; pp. 462 - 467
• Main Authors: Wyatt, J E, Pettit, W L, Harirforoosh, S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2012; Nature Publishing Group
• Subjects: 692/420/256; 692/700/565/1436/434; Anti-inflammatory agents; Anti-Inflammatory Agents, Non-Steroidal - metabolism; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Aryl Hydrocarbon Hydroxylases - genetics; Aspirin - therapeutic use; Biomedical and Life Sciences; Biomedicine; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac - analogs & derivatives; Diclofenac - therapeutic use; Drug therapy; Fever; Gene Expression; Genetic aspects; Genetic screening; Genomes; Human Genetics; Human Genome Project; Humans; Ibuprofen - therapeutic use; Indomethacin - therapeutic use; Inflammation; Nonsteroidal anti-inflammatory drugs; Oncology; Patients; Pharmacogenetics; Pharmacotherapy; Psychopharmacology; Pyrazoles - therapeutic use; review; Sulfonamides - therapeutic use; United States; cyclooxygenase; polymorphism; NSAIDs; pharmacogenetics
• ISSN: 1470-269X; 1473-1150
• DOI: 10.1038/tpj.2012.40

With the beginning of the Human Genome Project, an emerging field of science was brought to the forefront of the pharmaceutical community. Pharmacogenetics facilitates optimization of the current patient-centered care model and pharmacotherapy as a whole. Utilizing these ever-expanding branches of science to nonsteroidal anti-inflammatory drugs (NSAIDs) can provide novel opportunities to affect patient care. With a wide range of NSAID choices available as treatment options for relieving pain and/or reducing inflammation or fever, a more systematic way of selecting the ideal agent for the patients based upon their genetic information could spare them from a potentially permanent health-care condition. Furthermore, if a patient possesses or lacks certain alleles, serious adverse events can be anticipated and avoided. The tailoring of drug therapy can be achieved using the published data and cutting-edge genetic testing to attain a higher standard of care for patients.